Keep your family healthy | Top medical experts educate and help
Home » Coronavirus » COVID-19 coronavirus therapy. Anakinra in cytokine storm treatment. (10)
COVID-19 coronavirus therapy. Anakinra in cytokine storm treatment. (10)
Return to Expert Center
So indeed, there Interleukin one inhibitor was tried in COVID-19 coronavirus patients not as part of the double-blind, randomized clinical trials, but as a case series or single cases, perhaps. And as far as you’ve heard, anakinra worked, at least in some patients very well. I mean, we have to always as clinicians, be very, very careful of anecdote. It’s not always right. Sometimes it is. And for the individual patient, if it works great. You have to make sure it’s not something else that made the patient better or the disease just getting better on its own. There’s a lot of confounding factors. But this is a these are unusual times, right? So if COVID-19 coronavirus was a chronic disease, and we were trying to find a new drug that may be better or more tolerated, for example, for whatever condition it is that we want to treat. You know, we do randomized, blinded, controlled trials that’s kind of like our standard. And we may do multiple of them to be convinced, yes, this is a safe and appropriate drug, or its benefit outweighs its risks for this disease. But in hotspots for COVID-19 coronavirus, whether it’s northern Italy, New York, Philadelphia, or wherever it happens to be, these poor clinicians are watching these COVID-19 coronavirus patients die right in front of them. And lots of them, thousands of them. And so it’s not for me, I know it may be for many people, it’s not a stretch, to say, Well, some of the stuff that may that has helped us with other cytokines storms may be beneficial here. And so number one, we should be enrolling COVID-19 coronavirus patients in clinical trials if they’re available. And there are clinical trials ongoing all around the planet, including looking at this drug anakinra in a clinical trial in Italy studying that now. and other trials that are planned. and we have one here that hopefully will get up and running soon in Birmingham. But not just interleukin one blockers. they’re looking IL-6 blockers, gamma interferon, CCR five, a variety of approaches to treat the cytokine storm aspect of COVID-19 coronavirus disease. So but if you’re not In a clinical trial, or they’re not available, or you’re full, or the patient refuses them, and they’re dying, it’s hard to ignore that. And we should do everything we can if patients are in our intensive care, and that’s important, too, you know, and or if we learn there are antivirals, that’s important too. But I think out of desperation, you know, we’re human, we don’t want to see these people dying from COVID-19 coronavirus. And if there’s any chance that we can say them from COVID-19 coronavirus, yes, some clinicians have started treating with anakinra the other drugs out of clinical trials. And it’s understandable. And anecdotally, some of these therapies, maybe many of them seem to help. It’s not hard data, you know, and no one expects that. But the problem is, we may not have some of that hard data for a month or two or longer. And so how many people die in that process until we kind of know the right thing to do. It’s a very tough situation that we’re all in, particularly the physicians, nurses, restaurant therapists. Whoever on the front line with COVID-19 coronavirus fight. Professor Cron, is there a topic or question that I didn’t ask but should have asked? Is there anything in your interest or experience that you’d like to share with our international viewers? No, I think you’re very, very thorough, Anton. And I mean, I just come back to my drive home point with COVID-19 coronavirus. I think it’s pretty clear to many people, not everyone, but a lot of us that severe COVID-19 coronavirus infection is an aspect of a cytokine storm, including the respiratory distress that occurs. And in addition to treating the COVID-19 coronavirus and we have a lot of antiviral studies going on, it’s very important, we have vaccine development that will hopefully make this less of an issue a year or two from now or down the road. That’s critically important stuff. But in the immediacy of the situation, in addition to treating the COVID-19 coronavirus and supporting them as any intensive care would support someone who’s this ill, I think we need to target cytokine storm if it’s present. And this isn’t targeting a mild version of cytokine storm in COVID-19 coronavirus where you’re well enough to be at home and feel crummy. You know, we wouldn’t suggest that to anyone. so this isn’t to push these medicines outside of the hospital setting. And maybe that idea changes, I don’t know. But I think at this point, that’s certainly nothing that any of us would recommend. But I think like you were honing in on earlier. If we can get them before they get to the point where they require mechanical ventilation and intubation and any intensive care, then their chances if these therapies (like anakinra) work, if any or all of them work, that that’s the best time to be trying them probably. And in society, if we can keep people on ventilators and keep our intensive care units, the numbers down anything from what they are, that will be beneficial to everyone. Professor Cron, thank you very much for this most informative conversation in a very timely conversation as well. We hope to revert to you in the future. In contrast, more results are coming in, including those clinical trials and case series to treat cytokine storm syndrome. Thank you very much! Thank you.